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Background: One of the genes suggested to play an important role in the pathophysiology of bipolar disorder
(BPD) is PDLIM5, which encodes LIM domain protein. Our main objective was to examine the effect of olanzapine
treatment on PDLIM5 mRNA expression in the peripheral blood leukocytes of BPD patients.
Methods: We measured the expression of PDLIM5 mRNA from 16 patients with BPD Type I after 0, 4, and 8 weeks
of treatment with olanzapine using quantitative real-time PCR. The Young Mania Rating Scale was used to evaluate
the severity of manic symptoms in BPD patients. We also compared PDLIM5 mRNA expression in treatment-naïve
BPD patients with that in healthy control subjects.
Results: No significant difference was found in PDLIM5 mRNA expression between patients before olanzapine
treatment and following 4 and 8 weeks of treatment (p>0.05). Although we observed a significant reduction in the
severity of manic symptoms in all BPD patients (p<0.05), the effectiveness of the medication did not significantly
correlate with the expression of PDLIM5 mRNA (p>0.05). Interestingly, PDLIM5 mRNA expression differed significantly
between treatment-naïve BPD patients and healthy control subjects (p=0.002).
Conclusion: PDLIM5 mRNA expression did not appear to be a reflection of the efficacy of olanzapine in reducing
the manic symptoms of BPD. The significant difference in expression of PDLIM5 mRNA in the peripheral blood
leukocytes of treatment-naïve BPD patients versus that of healthy control subjects, however, suggests that it may
be a good biological marker for BPD.
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Bipolar disorder (BPD) is a mental illness that specific-
ally affects mood and has an estimated prevalence
of 0.8-2.6% [1]. Strong evidence from twin, adoption,
family, and linkage studies has shown that BPD is asso-
ciated with genetic factors, with an estimated heredity
of 63%[1]. On the basis of evidence reported in genetic
association and expression studies, PDLIM5 is a promis-
ing candidate gene for BPD [2].
The PDLIM5 gene lies on chromosome 4q22 and con-
sists of a PDZ (post-synaptic density-95/discs large/
zone occludens-1) domain and three LIM (Lin-11 Isl-1* Correspondence: aizat03@gmail.com
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reproduction in any medium, provided the ormec03) domains. LIM domains are cysteine-rich double
zinc fingers composed of 50 to 60 amino acids that are
involved in protein-protein interactions such as cyto-
skeleton organization, cell lineage specification, organ
development, and oncogenesis. LIM domains are also
members of the Enigma class of proteins, including the
Enigma homologue (ENH), a family of proteins that pos-
sess a 100-amino acid PDZ domain in the N terminus
and one to three LIM domains in the C terminus. The
PDLIM5 gene is ubiquitously expressed in the brain and
its cellular localization is identical to that of synapsin I,
which is known to be involved in neurotransmitter
release. The LIM domain is an intermediate protein that
can interact with various isoforms of protein kinase C
(PKC). LIM domains have been reported to modulate
intracellular calcium levels by linking N-type calcium
channels with PKC epsilon, thereby promoting the. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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perties [3]. The formation of the PKCε-ENH-N-type Ca2+
channel complex has been hypothesized to have an
important role in the molecular basis and efficiency of
cellular signalling [4,5].
In genetic association studies, single nucleotide poly-
morphisms (SNPs) that are located in the upstream
region of PDLIM5 have been found to be associated with
BPD [6,7], schizophrenia [8], and major depressive dis-
order [9]. In addition, previous studies showed a sig-
nificant association between BPD and haplotypes of
PDLIM5 polymorphisms located in the upstream region
[7,10]. However, other studies failed to replicate these
findings, possibly because of genetic heterogeneity or
methodological inconsistencies [11-13]. Expression stud-
ies had found that the mRNA expression of the PDLIM5
gene was increased in post-mortem brain tissue [14] and
decreased in lymphoblastoid cell lines [14,15] derived
from peripheral blood leukocytes (PBLs) of BPD
patients. The difference might be caused by a state-
related rather than a trait-related change in PDLIM5
gene action [12].
Alterations in PKC activity have been suggested to play
an important role in BPD and may be the core patho-
logical characteristic [16,17]. Novel findings confirmed
the molecular function of the LIM domain in regulating
PKC activity in a PKC isoform-specific manner [18].
PDLIM5 was also shown to promote shrinkage of
dendritic spines that may be associated with cognitive
impairment [19]. Previous pharmacotherapy studies
showed an interaction between lithium and the LIM
domain in improving manic symptoms in BPD through
the normalization of PKC activity [16,17]. On the other
hand, one study showed no interaction between lithium
prophylaxis and the LIM domain [20]. Currently, atyp-
ical antipsychotics that have mood stabilizer properties
are frequently used to treat BPD because of their
improved tolerability and efficacy [21]. Olanzapine, an
atypical antipsychotic used in the treatment of BPD, has
been shown in several studies to improve the symptoms
of mania [22-25]. We hypothesize that this effect of
olanzapine reflects in part its indirect interaction with
the LIM domain in the signalling cascade, leading to an
improvement in manic symptoms by normalizing PKC
activity. In this study, we compared PDLIM5 mRNA
expression in BPD patients before olanzapine treatment
and at 4 and 8 weeks after treatment. We also compared
PDLIM5 mRNA expression between treatment-naïve
BPD patients and control subjects. In addition, we exam-
ined the association between PDLIM5 mRNA expression
in treatment-naïve patients with BPD Type I and four
SNPs of the PDLIM5 gene located in the upstream
region: rs10008257, rs2433320, rs2433322, and rs2438146.Methods
The subjects in this study consisted of 16 patients with
BPD Type I (6 males, 10 females; mean age 40.25±14.6)
and 16 control subjects (8 females, 8 males; mean age
44.5±10.25). Patients were recruited from the inpatient
psychiatric clinic of University of Malaya Medical Centre
(UMMC), and control subjects were recruited from the
medical clinic of the UMMC. The protocol used in this
study was approved by the Medical Ethics Committee of
UMMC, and all subjects signed consent forms before
they participated in the study. All subjects reported an
absence of inter-ethnic marriage for at least three prior
generations. Demographic data were recorded, including
age, gender, marital status, education, occupation, ethni-
city, duration of illness, previous non-compliance, previ-
ous substance abuse, and family history of mental
illness. Only patients diagnosed with BPD Type I were
included in this study. Patient diagnosis was undertaken
by a qualified psychiatrist using the Mini International
Neuropsychiatric Interview assessment scale [26]. The
patients were confirmed as being treatment-naïve or as
having no history of psychotropic medication for at least
3 months. The progress of all patients was extensively
monitored during the 8 weeks of treatment with olanza-
pine. Patients were given 5 to 20 mg of oral olanzapine
daily, as assessed by the psychiatrist during the 8 weeks
of treatment. Severity of illness was evaluated by the
psychiatrist using the Young Mania Rating Scale (YMRS)
at three time points, namely, before medication and after
4 and 8 weeks of olanzapine treatment. Control subjects
were confirmed as having no history of mental illness
and no first-degree relatives with mental illness, having
no chronic disease, and not taking psychotropic medica-
tion or any other medications for chronic diseases.
Patient blood samples were collected in two tubes: a
Tempus BloodTM RNA Tube and an ethylenediaminete-
traaceticacid (EDTA) tube. The Tempus BloodTM RNA
Tube contains 6 ml of Applied Biosystems Stabilizing
Reagent, which immediately lyses blood cells after the
blood is drawn into the tube, whereas the sample in the
EDTA tube was used for DNA extraction. The RNA and
DNA were extracted from the blood using the Tempus
BloodTM RNA Extraction kit and QIAamp DNA Mini
Kit (Qiagen, Hilden, Germany), respectively. All proce-
dures of blood collection, storage, handling, and DNA
and RNA extraction of the samples followed standard pro-
tocols provided by the manufacturers. The quantity and
purity of the RNA and DNA were measured using Nano-
Drop (NanoDrop Technologies, Wilmington, DE, USA).
Expression of the PDLIM5 gene was quantified with
the StepOnePlusTMReal-Time PCR System with the
TaqMan® Gene Expression Assay and TaqMan® Gene
Expression Master Mix according to the manufacturer’s
Table 1 Demographic data of the 16 BPD patients in this
gene expression study
Characteristic Frequency Percentage
Gender Male 6 33.3
Female 10 55.6
Marital status Single 9 50
Married 5 27.8
Divorced 2 11.1
Education Primary 2 11.1
Secondary 7 38.9
Tertiary 7 38.9
Occupation Employed 7 38.9
Unemployed 9 50
Race Malay 4 22.2
Chinese 8 44.4
Indian 4 22.2
Duration of illness <5 y 6 33.3
6-10 y 4 22.2
11-20 y 2 11.1
>20 y 4 22.2
Previous non-compliance Yes 13 72.2
No 3 16.7
Previous substance abuse Yes 4 22.2
No 12 66.7
Family mental illness Yes 5 27.8
No 11 61.1
BPD bipolar disorder.
Table 2 Association between genotypes of PDLIM5 gene
polymorphisms and PDLIM5 mRNA expression in
treatment-naïve BPD patients*
SNP Genotype N Mean SD F p value
rs10008257 AA 2 0.3 0.078 0.348 0.713
AG 5 0.39 0.351
GG 8 0.27 0.205
rs2433320 GG 10 0.34 0.257 2.019 0.176
GA 4 0.16 0.107
AA 1 0.65 -
*Prior to medication with olanzapine.
BPD bipolar disorder, SNP single nucleotide polymorphism.
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Applied Biosystems (Assay ID: PDLIM5, Hs00179051_
m1). Glyceraldehyde-3-phosphate dehydrogenase was
used as an internal control for normalization. Samples
were run in real-time PCR in triplicate. We used the
comparative Ct method to calculate relative changes
in PDLIM5 gene expression following the subject’s
response to olanzapine medication. Data were collected
and analysed using StepOnePlusTM software version 2.1
(Applied Biosystems, Foster City,CA, USA).
In our preliminary study to investigate the association
between genotype and expression level of the PDLIM5
gene, we genotyped four SNPs of PDLIM5 (rs10008257,
rs2433320, rs2433322, and rs2438146) for the 16
treatment-naïve BPD patients using an inventoried Taq-
Man probes assay, TaqMan Genotyping Master Mix, and
StepOnePlusTMReal-Time PCR, following the protocol
provided by the manufacturer (Applied Biosystems).
Statistical calculations in this study were performed
using SPSS statistical software version 16.0. The distri-
butions of YMRS scores and PDLIM5 mRNA expression
were checked for normality using the Kolmogorov-
Smirnov test. The differences between PDLIM5 mRNA
expression in controls and patients, as well as in patients
before and after 4 and 8 weeks of olanzapine treatment,
were calculated using the Wilcoxon signed rank test.
The differences between the YMRS scores, however,
were determined using the Wilcoxon signed rank test
only in patients before and after 4 and 8 weeks of olan-
zapine treatment. A Spearman correlation coefficient test
was performed to investigate the association between
PDLIM5 mRNA expression and YMRS scores following
8 weeks of treatment. The SHEsis web-based platform
was used to calculate linkage disequilibrium between
the four SNPs of PDLIM5 [27]. A one-way analysis of
variance test was used to determine the association be-
tween PDLIM5 mRNA expression and genotypes of the
four SNPs of the PDLIM5 gene, as well as between
PDLIM5 mRNA expression and patient demographic data,
including duration of illness, previous non-compliance,
previous substance abuse, and family history with mental
illness, in treatment-naïve BPD patients. Hardy-Weinberg
equilibrium was checked for all four SNPs using the
Hardy-Weinberg calculator online tools [28].
Results
The demographic data of the patients in this study are
shown in Table 1. Among the 16 BPD patients recruited,
4 were Malay, 8 Chinese, and 4 Indian, whereas among
the control subjects, 9 were Malay, 5 Chinese, and 2 In-
dian. In our preliminary association study, we detected
three SNPs of the PDLIM5 gene in perfect linkage
disequilibrium (D’=1.00): rs2433320, rs2438146, and
rs2433322. Thus, we analysed only the rs2433320polymorphism as representative of the other two SNPs.
We observed no significant difference between the SNPs
of PDLIM5 and its mRNA expression in treatment-naïve
BPD patients (Table 2). As the sample size was small, we
did not stratify the samples into the different ethnicities.
The genotype distributions for the four SNPs were in
Hardy-Weinberg equilibrium for all patients.
Both the YMRS scores and PDLIM5 mRNA expression
were in normal distribution (p>0.05). We compared the
mean YMRS scores of patients before and after taking
Figure 2 PDLIM5 mRNA expression level in control subjects
and patients at 0, 4, and 8 weeks after olanzapine treatment.
The mean PDLIM5 mRNA expression level was significantly lower in
naïve patients than in control subjects (naïve patients: 0.31±0.245;
controls: 1.42±1.42; Wilcoxon rank sum test: *p=0.002). After 4 weeks
of treatment, no significant changes were detected in PDLIM5
mRNA expression when compared with the mean mRNA level in
treatment-naïve patients (after 4 weeks of treatment: 0.36±0.195;
Wilcoxon rank sum test: p=0.826). The PDLIM5 mRNA expression
level after 8 weeks was 0.36±0.244, with no statistical difference
when compared with the mRNA level after 4 weeks of treatment
(Wilcoxon rank sum test: p=0.937). The mean PDLIM5 mRNA
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observed that the mean YMRS score was significantly
reduced after 4 weeks of medication with olanzapine.
Furthermore, after 8 weeks of treatment, the mean
YMRS score was significantly lower than the mean
YMRS score after 4 weeks of medication (Figure 1). We
also compared the mean relative quantification (RQ)
levels before and after olanzapine treatment in order to
investigate the effects of olanzapine on PDLIM5 mRNA
expression in PBLs. We showed that there was no
significant difference between PDLIM5 mRNA expression
before and after 4 and 8 weeks of medication (Figure 2).
However, we observed that PDLIM5 mRNA expression
was significantly lower in BPD patients than in con-
trol subjects (Figure 2). Because it is well known that
genetic variation can cause considerable differences in the
response to medications among different ethnicities [29],
we stratified the sample by ethnicity. The results indicated
that there was a significant association between PDLIM5
mRNA expression and the occurrence of BPD in the In-
dian patients (p=0.028), with a trend towards a positive
association in the Chinese BPD patients (p=0.064). No
association was found between PDLIM5 mRNA expres-
sion and the occurrence of BPD in the Malay patients
(p=0.289). No further ethnic-based analysis was per-
formed following stratification into ethnic groups becauseFigure 1 The mean Young Mania Rating Scale (YMRS) score
before (0 weeks) and after 4 and 8 weeks of olanzapine
treatment in patients with bipolar disorder (BPD). The mean
YMRS score was significantly lower after 4 weeks of treatment with
olanzapine (mean YMRS score before medication: 30.31±10.81;
after 4 weeks of medication: 10.53±9.82; Wilcoxon rank sum test:
*p= 0.001). The mean YMRS score of the BPD patients was further
significantly reduced after 8 weeks after medication compared with
the score after 4 weeks of medication (YMRS score after 8 weeks
of medication: 2.5±2.20; Wilcoxon rank sum test: #p= 0.005).
The YMRS mean scores before and after treatment are indicated
by horizontal lines.
expression level in controls and patients before and after treatment
is indicated by horizontal lines.of the small sample size. It should be noted that, from the
YMRS scores, our clinician found that all 16 multi-ethnic
patients were responsive to olanzapine medication, hence
indicating that in this small population of multi-ethnic
subjects, there was no suggestion of ethnic variation in
response to medication.
No significant correlation was observed between
PDLIM5 mRNA expression and YMRS scores before
and after adjustment for age, gender, and ethnicity or be-
fore and after 4 and 8 weeks of olanzapine treatment
(Table 3). No significant association was observed be-
tween PDLIM5 mRNA expression and duration of illness
(F=1.156, p =0.37), previous non-compliance (F=0.233,
p=0.638), or previous substance abuse (F=0.644,
p=0.437), but a positive trend was observed towards
a significant association with a family history of mental
illness (F=3.427, p =0.087), as indicated by the finding
that 45% of the patients had a history of mental disease.
Discussion
The mechanism of antipsychotic drug action at the re-
ceptor level in reducing the symptoms of mania in BPD
is well explained as being due to the blockade of the D2
receptor; the antidepressant effect of the antipsychotics,
on the other hand, relates to the action of the 5-HT
Table 3 Correlation between YMRS score and RQ level
YMRS score vs. RQ Non-adjusted Adjusted for age, gender, and ethnicity
Pearson correlation p value (2-tailed) Pearson correlation p value (2-tailed)
Before medication −0.252 0.365 −0.236 0.460
At 4 weeks −0.180 0.539 −0.216 0.523
At 8 weeks −0.352 0.262 −0.210 0.587
RQ relative quantification, YMRS Young Mania Rating Scale.
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events downstream of the receptor is unclear. Many
studies relate mood disorder to abnormalities of neuro-
plasticity in the central nervous system. Changes in the
cellular signalling cascade are an example of a neuro-
plastic event. The cellular signalling cascade plays an
important role in the regulation of neuropeptide and
neurotransmitter systems and is also a target of psycho-
tropic drugs and hormones that are implicated in the
pathophysiology of BPD. Abnormality in the signalling
cascade could explain various neurovegetative symptoms
and medical comorbidity associated with BPD [31].
Olanzapine has been shown to activate certain signalling
cascade such as the JAK/STAT, Akt/PKB, p38, and
ERK1/2 pathways [32]. From these findings, it was sug-
gested that activation of the signalling cascade by olan-
zapine could alter the expression of genes involved in
the signalling cascade, leading to a positive therapeutic
effect [32].
We hypothesized that olanzapine administration
causes changes in the expression of PDLIM5 mRNA,
which encodes a protein that functions in the regulation
of PKC activity, leading to improvement of manic symp-
toms in BPD. We observed a significant reduction in
YMRS scores over 8 weeks of medication, indicating the
effectiveness of olanzapine medication in this BPD
group. Previous studies have also confirmed the effect-
iveness of olanzapine in the treatment of BPD [23,24,33].
However, we observed no significant changes in PDLIM5
mRNA expression over 8 weeks of treatment with olan-
zapine, nor did we find any correlation between im-
provement in manic symptoms of BPD and PDLIM5
mRNA expression. Interestingly, in a study of schizo-
phrenia patients, Numata et al. [12] showed that the
expression of PDLIM5 was significantly higher in the
leukocytes of treatment-naïve patients than it was in
control subjects. However, when these investigators
compared PDLIM5 expression between controls and
schizophrenia patients who were stable after receiving
antipsychotic medication for at least 3 months, they
observed no significant difference. They reported that
this finding may be a consequence of the pharmaco-
logical effects of antipsychotics or of clinical improve-
ment and suggested that the expression of PDLIM5
mRNA may not be a trait-oriented change, but a state-related one that may respond to environmental factors
such as antipsychotic medication [12]. It is notable that
the study was cross-sectional and that no specific anti-
psychotic medication was mentioned. In contrast, our
study did not show any correlation between PDLIM5
expression and olanzapine treatment. These contrasting
findings in the association between antipsychotics and
PDLIM5 expression may relate to differences in the
disease condition, that is, BPD and schizophrenia, or
to antipsychotic medication other than olanzapine. Our
results indicate a lack of interaction between PDLIM5
and olanzapine medication in improving the manic
symptoms of BPD.
Gene expression in peripheral blood is assumed to re-
flect the expression of the gene in the prefrontal cortex,
making it potentially useful as a surrogate marker for
mental disorder [34]. Moreover, components of the
immune system found in peripheral blood, such as
cytokines, lymphocytes, and interleukins, have also been
found in the central nervous system [34]. Thus, studying
mRNA expression in peripheral blood has been sug-
gested to reveal disease-specific immune changes and
provide a marker of disease progression. In our study,
we observed that PDLIM5 mRNA expression in PBLs
was significantly reduced in treatment-naïve BPD
patients compared with that in healthy control subjects.
Our results support previous findings that showed a
significant decrease in PDLIM5 mRNA expression in the
lymphoblastoid cell lines of BPD and schizophrenia
patients [14,15], as well as in the PBLs of patients with
major depressive disorder [13], compared with that in
control subjects. Our results also support previous
studies that suggested that the difference in expression
level of the PDLIM5 gene in PBLs between patients and
control subjects could be used as a potential biological
marker for mental disorder [12,13]. Further functional
studies with larger sample sizes are needed to confirm
the effectiveness of PDLIM5 in such a role.
One important factor that could affect gene expression
is genetic polymorphism. To examine the effect of SNPs
on the expression level of PDLIM5 mRNA in untreated
BPD, we genotyped four SNPs of PDLIM5 that have
previously been found to be significantly associated with
BPD [6,7]. We observed no significant correlation
between these four SNPs, located in the upstream region
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peripheral leukocytes. From these preliminary data, we
conclude that none of these SNPs significantly affected
the expression of PDLIM5 mRNA in PBLs. However, we
cannot exclude the possibility of a type II error, as our
sample size in this association study was relatively small.
Conclusion
In summary, we showed that there was no correlation
between PDLIM5 mRNA expression and clinical im-
provement in BPD patients during 8 weeks of olanzapine
treatment. We also found that PDLIM5 mRNA expres-
sion in PBLs was significantly lower in treatment-naïve
patients than in control subjects, but found no associ-
ation between each of the four SNPs of PDLIM5 and
mRNA expression level. Our results suggest that further
studies are warranted of PDLIM5 mRNA expression in
PBLs as a potential biological marker for BPD.
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